ERBB2 and gastric cancer: For example, in the case of the ERBB2-targeting monoclonal antibody trastuzumab, a phase 3 global study comparing chemotherapy with trastuzumab vs. chemotherapy with placebo for patients with HER2-positive advanced gastric cancer suggested differences in the OS achieved by Asians (OS HR = 0.82) compared to non-Asians (OS HR = 0.63 in Europeans and 0.44 in Central and South Americans) [134].